Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma

• Status: Completed
• Trial end date: 2014-02-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate among patients with untreated advanced ADC-CBA, impact on the disease control rate after 4 months treatment of an early therapeutic permutation with the first month in the absence of stabilization or objective answer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Intergroupe Francophone de Cancerologie Thoracique
• Treatments: Carboplatin; Erlotinib Hydrochloride; Paclitaxel

Criteria

Inclusion Criteria:

• CBA histologically proven (or cytologically with pneumonic presentation) PS < 3 signed and written informed consent

Exclusion Criteria:

• visible tumoral lesion in bronchial fibroscopy